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Abstract
Background: Whether long-chain n–3 PUFAs of marine origin have an anti-atherogenic effect in the general
population has hardly been studied. In this population-based study, we hypothesized that fatty fish and fish oil
intake protect against development of novel atherosclerotic plaques and is associated with reduced plaque size.
Methods: We obtained questionnaire-based information on fish consumption and carotid ultrasonography from
3900 persons aged 45–74 years. The questionnaires were validated by measuring serum concentrations of PUFAs
and triglycerides in a subgroup. At follow-up seven years later, 2983 (76%) went through a second ultrasound
scanning. Logistic regression and general linear models were used to analyze the outcome (plaque presence and
plaque area) as a function of fish consumption, including analyses stratified on fish oil supplements.
Results: At baseline, lean fish intake < 1 time/week vs. 1–1.9 times/week was associated with risk of plaque (OR 1.34, 95%
CI 1.03–1.76). Fatty fish intake and use of fish oil supplements were not statistically significantly associated with
atherosclerosis at baseline. In persons without plaque at baseline, total fish consumption ≥3 times/week vs.
1–1.9 times/week was associated with risk of novel plaque (OR 1.32, 95% CI 1.01–1.73) and larger plaque area
(1.76 mm2 vs. 1.46 mm2, p = 0.02) at follow-up. Adjustments for use of fish oil supplements had no impact on
the associations, and no interactions were seen between total, fatty or lean fish consumption and fish oil intake.
Conclusions: We found no protective effect of fatty fish eating or fish oil supplements on atherosclerotic plaque
formation or plaque area in a general population. Lean fish consumption was associated with a reduced risk for
plaque in cross-sectional analysis, suggesting that the beneficial effects of fish consumption on atherosclerosis
may be mediated through other mechanisms than n-3 PUFAs.
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Background
Epidemiological, animal, and cell culture studies show that
long-chain n–3 PUFAs of marine origin, eicosapentaenoic
acid (EPA), docosahexaenoic acid (DHA) and docosapen-
taenoic acid (DPA), reduce the risk of cardiovascular dis-
eases (CVD). Fatty fish and fish oils are rich sources of
these fatty acids. The most compelling evidence for car-
diovascular benefits of n-3 PUFAs comes from 4 con-
trolled trials of nearly 40,000 participants randomized to
receive EPA with or without DHA in primary prevention
[1], after myocardial infarction (MI) [2, 3], and in heart
failure [4]. However, recent meta-analyses including newer
randomized trials found that, except for a 10% reduction
in sudden cardiac death among patients with prior MI,
n-3 PUFA supplementation was not associated with a
lower risk of all-cause mortality, non-fatal MI, or stroke
[5, 6]. Taken together, the cumulative evidence suggests
that n-3 PUFA supplements may reduce cardiac death in
patients with prior MI, possibly through a reduction in
ischemia-induced ventricular fibrillation [6]. In the recent
updated advisory report, the American Heart Association
has endorsed the use of n-3 PUFA at a dose of approxi-
mately 1 g/day, either in the form of fatty fish or fish oil
supplements in patients with a previous MI or in
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patients with heart failure without preserved left ven-
tricular function [6].
N − 3 PUFAs can influence many aspects of the patho-
genesis of CVD, including inflammation [7], arrhythmias
[8–12], platelet aggregation [13, 14], hypertension [15–17],
and hyperlipidemia [18–20]. Although most evidence
points to an antiarrhythmic effect, several studies have sug-
gested that n-3 PUFAs may also have favorable effects on
the pathogenesis of atherosclerosis. Fish oil has prevented
the development of experimental atherosclerosis in pigs
and rhesus monkeys [21–23]. In humans, a case-control
study on peripheral arterial disease found that plasma
levels of DPA related inversely to blocked arteries [24].
Cross-sectional studies with carotid ultrasonography re-
vealed that carotid artery wall thickness decreased with
EPA, DHA and DPA intake [25, 26]. A population
based prospective study of atherosclerosis in men aged
40–49 years showed that serum concentrations of n-3
PUFAs contributed to the difference incidence of cor-
onary artery calcification between Japanese and US
white men [27].
Whether any anti-atherosclerotic effects of fish con-
sumption is due to biological effects of n-3 PUFAs, or
fish intake itself, due to replacement of other less favor-
able foods, has not been clearly addressed. An observa-
tional study in postmenopausal women found that after
3.2 years of follow-up, the consumption of ≥2 servings
of fish or ≥ 1 serving of tuna or dark fish each week was
associated with less progression of coronary artery stenosis
[28]. A recent Italian study of 961 persons aged 18–89 y
without clinically known atherosclerotic disease found that
consuming ≥2 vs. < 1 serving of fish weekly was protective
against carotid atherosclerosis defined as common carotid
intima media thickness (cIMT) ≥ 0.9 mm or a focal plaque
of > 1.2 mm [29]. According to The European Society of
Cardiology (ESC)/European Society of Hypertension
(ESH) guidelines (2013) SCORE Chart, asymptomatic vas-
cular damage is defined as the presence of IMT > 0.9 mm
or a focal plaque.
In this observational population-based study, we inves-
tigated the association between habitual fish consump-
tion, fish oil consumption and carotid atherosclerosis
defined as the presence of plaques on ultrasound assess-
ment. We hypothesized that fatty fish and fish oil intake
protect against development of novel atherosclerotic pla-




For this study, we used cross-sectional and prospective
data from the 4th (1994–95) and 5th survey (2001) of
the Tromsø study [30]. In the 4th survey (baseline), valid
information on carotid plaque number, plaque area and
fish consumption was obtained in 4589 persons aged
45–74. We excluded 689 persons with previous angina
pectoris, MI or stroke, leaving 3900 eligible for the
present study. Valid information on fish oil supple-
ments was available in 3290 participants. In the 5th sur-
vey (follow-up), 2983 out of the 3900 subjects (76%)
underwent a new valid ultrasound scanning, in whom 2535
persons had valid information on fish oil supplements.
Ethics
The Norwegian Data Inspectorate licensed all data. The
Regional Committee for Research Ethics approved the
study (REC no. 200005785–7/IAY/400). All the partici-
pants gave their written informed consent.
Assessment of fish consumption and fish oil supplements
At baseline, information of weekly consumption of fish
for dinner and intake of fish oil supplements was
assessed through a self-administered questionnaire. For
participants aged < 70 years, the questionnaire covered
37 food frequency items, whereas those aged ≥70 years
filled in a simplified questionnaire that covered only 23
food frequency items. Participants were asked how many
times per week they usually ate fatty and lean fish, re-
spectively (in the analyses categorized into four groups:
never, < 1 time/week, 1 time/week, ≥2 times/week).
Total weekly consumption of fish (times per week) was
calculated by combining the answers given to the fatty
and lean fish questions, and categorized into the follow-
ing categories: < 1 time/week, 1–1.9 times/week, 2–2.9
times/week, and ≥ 3 times/week. According to the Nor-
wegian Directorate of Health, a normal serving size of
fish is 150 g. Participants were additionally asked to re-
port how many months during the last year they had
taken fish oil supplements on a daily basis. Intake of fish
oil supplements was categorized as “no supplements”
(no months during last year) and “supplements” (any
number of months during the last year). The validity and
reproducibility of dietary data from self-administered
questionnaires in the Tromsø cohort have been reported
previously [31, 32]. Additionally for this study, we vali-
dated the questionnaire based dietary assessment on fish
servings and fish oil supplementation in a subgroup of
1656 participants by measuring serum concentrations of
n-3 PUFAs and exploring the expected triglyceride-lowering
effect of n-3 PUFAs [33].
Cardiovascular risk factors
Height and weight were measured standardized. Body
mass index (BMI) was calculated as weight in kilograms,
divided by the square of height in meters (kg/m2).
Specially trained personnel recorded blood pressure with
an automatic device (Dinamap Vital Signs Monitor,
Tampa Fla) with the participants in sitting position after
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2 min rest. Three readings of blood pressure (on the
upper right arm) were taken, separated with a 1-min
interval. We used the average of the last two measure-
ments in the analyses. Non-fasting serum total choles-
terol and triglycerides were analyzed by enzymatic
colorimetric methods with commercial kits (CHOD-
PAP for cholesterol and GPO-PAP for triglycerides;
Boehringer-Mannheim). Serum HDL cholesterol was
measured after precipitation of lower-density lipopro-
tein with heparin and manganese chloride. LDL choles-
terol was estimated using the Friedewald equation.
Fibrinogen was measured with the PT-Fibrinogen re-
agent (Instrumentation Laboratory). Monocytes and
white blood cells were counted with automated cell coun-
ters by standard techniques. CRP was analyzed in thawed
aliquots after storage at − 70 °C with a particle-enhanced
immunoturbidimetric assay on a Modular P with reagents
from Roche Diagnostics (Roche, Mannheim, Germany).
The Department of Clinical Chemistry, University
Hospital of North Norway, did all the blood sample
analyses. Information concerning education (in the
analyses dichotomized to education at college/univer-
sity level (yes/no)), leisure physical activity (sweating/-
out of breath ≥1 h/week (yes/no)), coffee consumption
(cups/day), previous MI, prevalent angina pectoris and
diabetes mellitus (yes/no), and cigarette smoking (never/-
previously/currently) was obtained from a questionnaire
enclosed in the letter of invitation. We defined present
coronary heart disease (CHD) as self-reported prevalent
angina pectoris or previous MI.
Ultrasonography and measures of atherosclerosis
The ultrasound methods and reproducibility of carotid
examination have been detailed elsewhere [34, 35]. At
baseline and follow-up, we used identical ultrasound im-
aging system (Acuson Xp10 128, ART upgraded, with a
7.5-MHz linear-array transducer, aperture size 38 mm).
Six locations in the right carotid artery (the far and near
walls of the common carotid, the bulb, and the internal
carotid) were scanned for the presence of plaque (yes/no)
and the number of plaques were registered. In Adobe
Photoshop v7.0, we analyzed still images of each plaque,
and the area (mm2) was calculated. In participants with
more than one plaque, the sum of plaque areas was taken
as the total plaque area (TPA). Novel plaque formation
was defined as ≥ one new plaque at follow-up in persons
with no plaque at baseline. The difference in TPA between
baseline and follow-up (ΔTPA) was calculated.
Statistics
Descriptive statistics (means or percentages) were com-
puted for each independent baseline variable in cat-
egories of fish consumption. Presence of plaque and
TPA were the dependent variables in the regression
models. TPA at baseline and follow-up (but not ΔTPA)
was square-root-transformed to approximate normal
distribution. Fish consumption (total, fatty fish and lean
fish) was the main explanatory variable. Predefined risk
factors for atherosclerosis (systolic blood pressure, current
smoking, total cholesterol, HDL-cholesterol, triglycerides,
diabetes, leucocyte count, monocyte count, fibrinogen,
CRP and anti-hypertensive medication) were introduced
as co-variables to adjust for confounding. First, we ana-
lyzed the whole sample on fish consumption without fish
oil in the models. Analyses were then repeated in models
stratified by fish oil supplements (yes/no). Logistic regres-
sion and general linear models were used to model the
outcome (plaque presence and TPA, respectively) as a
function of fish consumption. Linear trends across level
of fish intake were tested by logistic regression for cate-
gorical dependent variables and by linear regression for
continuous dependent variables. Statistical analyses
were conducted with SAS version 9.4 software (SAS
Institute, Cary, NC), and two-sided P < 0.05 was con-
sidered statistically significant.
Results
Table 1 lists baseline characteristics in the different cate-
gories of fish servings. Elderly men consumed more fish
than relatively younger women did. There was an inverse
trend between the number of fish servings per week and
serum triglycerides (p = 0.002). Leucocyte count was
positively associated with fish consumption (p = 0.05).
Participants who consumed fatty fish ≥2 times/week
(n = 608) were older, more likely to be males, daily
smokers, used more fish oil supplements and
lipid-lowering drugs, and had higher levels of CRP
(Table 2) than subjects with less frequent fatty fish
intake. The use of fish oil supplements was associ-
ated with female sex, higher education, physical ac-
tivity, not being a daily smoker, less boiled coffee
drinking, as well as lower BMI, serum triglycerides,
monocyte concentration, white cell count, fibrinogen
and CRP (Table 3).
Fish consumption and risk for plaque and TPA at baseline
At baseline, at least one plaque was present in 1884 of
the 3900 (48.3%) persons. There was a statistically sig-
nificant inverse trend (p = 0.02) between lean fish intake
and plaque prevalence (but not TPA). Lean fish intake
< 1 time/week vs. 1–1.9 times/week was associated with
34% increased risk of plaque (OR 1.34, 95% CI 1.03–
1.76), whereas no significant associations were found
between total or fatty fish intake and plaque prevalence
or TPA (Table 4). Among the 3290 persons with avail-
able information about the use of fish oil supplements,
the age- and sex-adjusted plaque prevalence (47.3% vs.
47.9%, p = 0.7) and square-root-transformed TPA levels
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(1.92 vs. 2.01 mm2, p = 0.3) were similar in users and
non-users.
Fish consumption and plaque at follow-up
At follow-up, at least one plaque was present in 1869 of
the 2983 (62.7%) persons who had a new ultrasound
scan. This includes subjects with a plaque present already
at baseline and subjects with a novel plaque. Both total
fish (p-trend = 0.05) and fatty fish (p-trend = 0.02) con-
sumption were positively associated with plaque preva-
lence (but not with TPA). No associations were found
between lean fish consumption and plaque prevalence or
TPA (results not shown in table). Among the 2535 per-
sons with available information on fish oil supplements,
the plaque prevalence (62.0% vs. 62.4%, p = 0.8) and
square-root-transformed TPA levels (2.73 vs. 2.84 mm2,
p = 0.3) were similar in users and non-users. Also, the
change in TPA (Δ TPA) between baseline and follow-up
(5.84 vs. 6.00 mm2, p = 0.8) was similar in users and
non-users of fish oil supplements.
Of the 2016 persons with no plaque at baseline, 1634
(81%) were re-examined at follow-up, At least one novel
plaque had developed in 700 (42.8%) of these. The risk
of novel plaque and TPA increased linearly by number
of total fish servings (Table 5). Total fish intake ≥3 time-
s/week vs. 1–1.9 times/week was associated with 32%
higher risk of novel plaque (OR 1.32, 95% CI 1.01–1.73)
and larger TPA (1.76 mm2 vs. 1.46 mm2). Among the
1400 persons with available information on use of fish
oil supplements, the prevalence of novel plaque (44.0%
vs. 41.7%, p = 0.4) and square-root-transformed TPA
level (1.63 vs. 1.62 mm2, p = 0.9) were similar in users
and non-users of fish oil supplements.
Analyses adjusted for fish oil supplements
All analyses above were repeated in models restricted to
subjects with available information about the use of fish
Table 1 Distribution of baseline characteristics across categories of fish consumption: the Tromsø Study
Fish servings, times per week









Age, y 58.4 (0.4) 59.3 (0.2) 61.8 (0.2) 63.0 (0.2) < 0.0001
Male, % 40.8 46.6 54.1 55.0 < 0.0001
Higher education, %a 16.9 20.3 17.6 18.9 0.8
Physical active, % 19.8 23.0 24.5 23.4 0.4
BMI, kg/m2 26.4 (0.2) 25.9 (0.1) 25.9 (0.1) 26.1 (0.1) 0.9
Total cholesterol, mmol/L 6.83 (0.08) 6.77 (0.03) 6.79 (0.04) 6.78 (0.03) 0.9
LDL cholesterol, mmol/L 4.48 (0.07) 4.44 (0.03) 4.46 (0.04) 4.48 (0.03) 0.7
HDL cholesterol, mmol/L 1.50 (0.03) 1.56 (0.01) 1.57 (0.01) 1.57 (0.01) 0.07
LDL/HDL ratio 3.20 (0.07) 3.12 (0.03) 3.05 (0.04) 3.10 (0.03) 0.3
Triglycerides, mmol/L 1.85 (0.06) 1.68 (0.03) 1.66 (0.03) 1.61 (0.03) 0.002
Systolic blood pressure, mmHg 146.7 (1.3) 144.4 (0.6) 146.2 (0.7) 145.5 (0.6) 0.6
Diastolic blood pressure, mmHg 85.2 (0.8) 83.4 (0.3) 84.4 (0.4) 83.9 (0.3) 0.9
Hypertension, % 60.2 53.9 56.9 56.4 0.7
Current smoking, % 29.3 31.1 31.2 33.7 0.09
Diabetes, % 2.5 2.8 1.7 2.8 0.9
Fish oil supplements, %b 45.6 50.5 45.1 52.4 0.2
Antihypertensive medication, % 11.7 10.3 10.7 9.8 0.4
Lipid-lowering medication, %c 0.8 1.7 1.1 1.9 0.4
Leukocyte count, × 109/L 6.76 (0.12) 6.84 (0.05) 6.95 (0.06) 6.95 (0.05) 0.048
Monocyte count, × 109/L 0.59 (0.01) 0.58 (0.01) 0.59 (0.01) 0.59 (0.01) 0.2
Fibrinogen, g/L 3.39 (0.05) 3.38 (0.02) 3.37 (0.03) 3.40 (0.02) 0.7
LogCRP, mg/ml 0.31 (0.07) 0.26 (0.03) 0.22 (0.04) 0.26 (0.03) 0.6
Age was sex-adjusted and sex was age-adjusted. All other variables were age- and sex-adjusted means (SE) or %
BMI body mass index
aCollege or university
b610 (15.6%) participants had missing information on fish oil supplements
cParticipants < 70 years
Johnsen et al. Nutrition Journal  (2018) 17:56 Page 4 of 9
oil supplements. Adjustments for this variable had no
impact on the associations, and no interactions were
seen between total, fatty or lean fish consumption and
fish oil intake.
Discussion
In this study, we found no protective effect of fatty fish
intake or fish oil supplements on atherosclerosis
assessed by carotid ultrasound. If anything, the associ-
ation was positive. At baseline (Table 4), we found that
lean fish consumption, if anything, reduced the odds of
having carotid plaque. However, in prospective ana-
lyses, this finding could not be reproduced and total
fish intake was actually associated with an increased
risk of novel plaque formation in persons without
pre-existing plaque.
As expected, we found an inverse trend between total
fish consumption and serum triglycerides (Table 1) and
that fish oil supplements were associated with low tri-
glycerides (Table 3). However, no statistically significant
inverse relationship was found between the intake of
fatty fish and serum triglycerides (Table 2). It is well
known that smoking increases serum triglyceride levels.
In our study, the age- and sex adjusted triglyceride levels
in smokers and non-smokers were 1.71 and 1.64 mmol/L,
respectively (p = 0.06). Thus, the higher proportion of
smokers in the high fatty fish consumption categories
could potentially explain the lack of inverse association
between fatty fish intake and triglyceride levels. High tri-
glycerides are not directly atherogenic, but represent an
important biomarker of cardiovascular risk because of
their association with atherogenic VLDL remnant particles
Table 2 Baseline characteristics stratified by fatty fish consumption: the Tromsø study
Fatty fish servings, times per week







Age, y 60.3 (0.2) 61.3 (0.2) 63.6 (0.3) < 0.0001
Male, % 49.6 50.4 57.1 0.009
Higher education, %a 18.2 19.9 18.3 0.6
Physical active, % 23.2 23.0 24.4 0.7
BMI, kg/m2 25.9 (0.1) 26.0 (0.1) 26.1 (0.2) 0.4
Total cholesterol, mmol/L 6.77 (0.03) 6.80 (0.03) 6.77 (0.05) 0.9
LDL cholesterol, mmol/L 4.45 (0.03) 4.48 (0.03) 4.46 (0.05) 0.8
HDL cholesterol, mmol/L 1.55 (0.09) 1.57 (0.01) 1.56 (0.02) 0.3
LDL/HDL ratio 3.10 (0.03) 3.09 (0.03) 3.13 (0.05) 0.9
Triglycerides, mmol/L 1.69 (0.02) 1.65 (0.03) 1.63 (0.04) 0.2
Systolic blood pressure, mmHg 145.4 (0.5) 145.1 (0.5) 146.1 (0.9) 0.7
Diastolic blood pressure, mmHg 84.0 (0.3) 83.6 (0.3) 84.6 (0.5) 0.7
Hypertension, % 55.8 55.3 58.3 0.5
Current smoking, % 30.7 32.0 35.7 0.04
Coffee consumption, cups/d
Boiled coffee 3.1 (0.1) 2.9 (0.1) 3.1 (0.2) 0.5
Other coffee 2.7 (0.1) 2.7 (0.1) 2.7 (0.1) 0.8
Diabetes, % 2.1 2.9 2.9 0.2
Fish oil supplements, %b 45.8 52.0 55.1 < 0.0001
Antihypertensive medication, % 11.0 9.1 11.5 0.7
Lipid-lowering medication, %c 1.1 1.9 2.7 0.02
Leucocyte count, × 109/L 6.86 (0.04) 6.89 (0.05) 7.05 (0.08) 0.08
Monocyte count, × 109/L 0.58 (0.004) 0.59 (0.005) 0.60 (0.008) 0.3
Fibrinogen, g/L 3.37 (0.02) 3.38 (0.02) 3.44 (0.04) 0.1
logCRP, mg/L 0.23 (0.03) 0.26 (0.03) 0.35 (0.05) 0.04
Age was sex-adjusted and sex was age- adjusted. All other variables were age- and sex-adjusted means (SE) or %
BMI body mass index
aCollege or university
b610 (15.6%) participants had missing information on fish oil supplements
cParticipants < 70 years
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and apo C-III, a proinflammatory, proatherogenic protein
found on all classes of the plasma lipoproteins [36].
Unexpectedly, we found no protective effect of fatty
fish intake or fish oil supplements, both containing high
amounts of n-3 PUFAs, on the risk for atherosclerosis.
The evidence for an anti-atherogenic effect of n-3
PUFAs is admittedly not very strong. The studies that
have shown effects are in general small, cross-sectional,
have reported on cIMT and not plaque, or have been
conducted in patients with previous CVD or high risk
for CVD. A small randomized trial (n = 59) did not de-
tect significant effects of fish oil supplementation
(6 g/day for 2.3 years) on the progression of coronary
atherosclerosis as measured by coronary angiography
[37]. A larger randomized trial (n = 223) found modest
effects of fish oil supplementation (1.65 g/day for two
years) on coronary atherosclerosis as measured by cor-
onary angiography [38], but not on carotid atheroscler-
osis as measured by ultrasound [39]. A third open-label
randomized trial evaluated the effects of EPA (1.8 g/day
for 2.1 years) on progression of carotid atherosclerosis in
81 Japanese patients with type 2 diabetes. Individuals
randomized to EPA had less progression of both mean
and maximal intimal medial thickness [40]. Although
these small clinical studies suggest that fish oil con-
sumption may modestly reduce progression of athero-
sclerosis, we could not reproduce this effect in a large
general population. When looking closer into the 541
participants who consumed fatty fish ≥2 times/week
(Table 2), we found that they were older, were more
likely to be males and smokers, and had higher levels of
CRP. On the other hand, users of fish oil supplement
had a more favorable risk factor profile compared to
non-users, implying that those who take fish oil supple-
ments have a healthier lifestyle.
An interesting question is whether fish consumption
itself, independent of n-3 PUFAs, can protect against
atherosclerosis due to replacement of other less healthy
foods. It is now increasingly recognized that the benefi-
cial effects of fish consumption is not limited to lipids
and fatty acids, but that the peptides and amino acids
like taurine and glycine, together with vitamins, are also
important for disease prevention [41]. Lean fish contains
Table 3 Baseline characteristics in users and non-users of fish







Age, y 61.4 (0.2) 60.6 (0.2) 0.0007
Male, % 49.0 55.7 0.0001
Higher education, %a 25.0 16.0 < 0.0001
Physical active, % 27.2 23.0 0.005
BMI, kg/m2 25.6 (0.1) 26.3 (0.1) < 0.0001
Total cholesterol, mmol/L 6.73 (0.03) 6.80 (0.03) 0.09
LDL cholesterol, mmol/L 4.43 (0.03) 4.48 (0.03) 0.2
HDL cholesterol, mmol/L 1.57 (0.01) 1.55 (0.01) 0.3
LDL/HDL ratio 3.09 (0.03) 3.12 (0.09) 0.4
Triglycerides, mmol/L 1.61 (0.03) 1.70 (0.03) 0.02
Systolic blood pressure, mmHg 144.6 (0.5) 145.4 (0.5) 0.2
Diastolic blood pressure, mmHg 83.5 (0.3) 84.0 (0.3) 0.2
Hypertension, % 54.1 55.8 0.3
Current smoking, % 28.7 34.8 0.0002
Coffee consumption, cups/d
Boiled coffee 2.3 (0.09) 3.5 (0.09) < 0.0001
Other coffee 2.9 (0.08) 2.6 (0.08) 0.009
Diabetes, % 2.1 2.4 0.6
Antihypertensive medication, % 10.4 9.5 0.4
Lipid-lowering medication, %b 2.0 1.1 0.04
Leucocyte count, × 109/L 6.80 (0.05) 6.95 (0.05) 0.02
Monocyte count, × 109/L 0.58 (0.004) 0.59 (0.004) 0.04
Fibrinogen, g/L 3.33 (0.02) 3.40 (0.02) 0.01
LogCRP, mg/L 0.20 (0.03) 0.27 (0.03) 0.04
Age was sex-adjusted and sex was age- adjusted. All other variables were
age- and sex-adjusted means (SE) or %
BMI body mass index
aCollege or university
bParticipants < 70 years
Table 4 Risk for plaque and total plaque area at baseline












< 1 258 124 (48.1) 1.29 (0.95–1.74) 2.17 (0.14)
1–1.9 1325 594 (44.8) 1 (Reference) 2.01 (0.06)
2–2.9 977 459 (47.0) 0.86 (0.71–1.04) 1.86 (0.07)
≥ 3 1340 707 (52.8) 1.01 (0.84–1.20) 2.03 (0.06)
p-trend 0.4 0.7
Fatty fish
< 1 1841 832 (45.2) 0.95 (0.82–1.11) 1.94 (0.05)
1–1.9 1518 738 (48.6) 1 (Reference) 1.99 (0.06)
≥ 2 541 314 (58.0) 1.20 (0.96–1.51) 2.16 (0.10)
p-trend 0.06 0.07
Lean fish
< 1 330 163 (49.4) 1.34 (1.03–1.76) 2.18 (0.13)
1–1.9 1437 652 (45.4) 1 (Reference) 1.99 (0.06)
≥ 2 2133 1069 (50.1) 0.93 (0.80–1.09) 1.96 (0.05)
p –trend 0. 02 0.2
Models were adjusted for age, sex, systolic blood pressure, current smoking,
total cholesterol, HDL-cholesterol, triglycerides, diabetes, leucocyte count,
monocyte count, fibrinogen, CRP and anti-hypertensive medication
TPA Total plaque area
aSquare root transformed
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less energy than fatty fish and has been associated with
less risk for metabolic syndrome [42]. At baseline, we
found that consumption of lean fish, which contains very
low levels of n-3 PUFAs, was inversely associated to
plaque prevalence, and that the effect remained significant
after adjustment for fish oil supplements. These findings
suggest that mechanisms other than those mediated
through fatty acids from fish consumption may be of
importance.
Studies have suggested that the preparation method,
frying in particular, may substantially alter the fatty acid
content of a fishmeal [43]. A study by Mozaffarian et al.
found that fried fish and fish sandwich consumption was
not associated with lower risk for ischemic heart disease,
arrhythmic death, or nonfatal myocardial infarction but
rather with trends towards higher risk [44]. In addition,
data from the Multi-Ethnic Study of Atherosclerosis
showed that the dietary intake of non-fried fish was in-
versely associated with the prevalence of subclinical ath-
erosclerosis defined as thickening of the common
carotid intima media thickness [45]. Unfortunately, we
lack specific registrations of differences in fish cooking
procedures and nutrients that may influence the impact
of fish intake.
Strengths of this study include the prospective design
and a large general population with high attendance rate.
As persons with cardiovascular diseases are more likely
to have carotid plaque when compared to those without
and at the same time might eat more fish for their vas-
cular health, we excluded all participants with previous
angina, MI and stroke to minimize confounding. We
further validated the reliability of dietary assessment on
fish servings and fish oil supplementation by measuring
serum concentrations of n–3 PUFAs and exploring the ex-
pected triglyceride-lowering effect of n–3 PUFAs. Plaque
presence and plaque area are considered as more robust
measures of subclinical atherosclerosis than cIMT [46].
The study also has limitations, however. First, residual
confounding can be expected. Even though we excluded
persons with previous cardiovascular diseases, and made
multiple adjustments, differences in lifestyle between
groups may have biased the associations between fish
consumption and atherosclerosis. Second, particularly
regarding the relationships between fish intake and the
risk of novel plaques, several of the risk factors may
have changed over time, including fish consumption,
which may lead to non-differential misclassification,
and thereby underestimation of the true associations.
Third, we lack specific registrations of differences in
fish cooking procedures and nutrients that may influ-
ence the impact of fish intake. Even though we ex-
cluded persons older than 74 years, the use of a
self-report questionnaire to obtain dietary intake data
may be subject to recall bias, thus introducing error
Table 5 Risk for plaque and total plaque area at follow-up in persons with no plaque present at baseline, according to categories of
fish consumption: the Tromsø Study









< 1 116 44 (37.9) 0.98 (0.62–1.54) 1.52 (0.19)
1–1.9 596 225 (37.8) 1 (Reference) 1.46 (0.08)
2–2.9 416 181 (43.5) 1.15 (0.87–1.52) 1.62 (0.10)
≥ 3 506 250 (49.4) 1.32 (1.01–1.73) 1.76 (0.09)
p-trend 0.04 0.02
Fatty fish
< 1 829 332 (40.1) 0.90 (0.72–1.13) 1.54 (0.07)
1–1.9 631 280 (44.4) 1 (Reference) 1.63 (0.08)
≥ 2 174 88 (50.6) 1.18 (0.81–1.72) 1.75 (0.16)
p-trend 0.1 0.2
Lean fish
< 1 142 55 (38.7) 0.99 (0.65–1.49) 1.57 (0.17)
1–1.9 636 253 (39.8) 1 (Reference) 1.52 (0.08)
≥ 2 856 392 (45.8) 1.12 (0.89–1.41) 1.66 (0.07)
p –trend 0.4 0.3
Models were adjusted for age, sex, systolic blood pressure, current smoking, total cholesterol, HDL-cholesterol, triglycerides, diabetes, leucocyte count, monocyte
count, fibrinogen, CRP and anti-hypertensive medication
TPA Total plaque area
aSquare root transformed
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into our estimated models. A weakness of the study is
related to loss of follow-up, which may have attenuated
the results. Although we used a standardized protocol
for the measurement of plaque at both baseline and
follow-up, plaque assessment may be distorted by
measurement error. Plaques of low echogenicity may
have been overlooked. Any such misclassification is ex-
pected to underestimate the true association.
Conclusions
In conclusion, we found no protective effect of fatty fish
consumption or use of fish oil supplements on risk of
atherosclerosis. In cross-sectional analyses, we found a
preventive effect of lean fish eating on atherosclerotic
plaque prevalence. The findings suggest that the beneficial
effects of fish consumption on atherosclerosis may be me-
diated through other mechanisms than n-3 PUFAs.
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